Avita Medical, Inc. · NASDAQ:RCEL
Avita Medical — Investor Presentation (April 2026)
28 slides from Avita Medical's investor presentation, Apr 17, 2026
Slide 1: AVITA Medical Cohealyx Call Investor Presentation
For personal use only AVITA Medical Cohealyx Call Investor Presentation April 16, 2026 1
Slide 2: Cohealyx I Interim Analysis Readout
For personal use only Cohealyx I Interim Analysis Readout 2
Slide 3: Forward-Looking Statements & Legal Disclaimers
Forward-Looking Statements & Legal Disclaimers This presentation and the accompanying oral commentary may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are predictions and subject to significant risks and uncertainties
Slide 4: Participants
Participants For personal use only Cary Vance Katie Bush, PhD Derek Bell, MD Lourdes Castañón, MD, FACS Interim Chief Senior Vice President, University of University of Arizona, Executive Officer Scientific and Medical Rochester Burn & Acute Care Surgery AVITA Medical Affairs Trauma Center, Plastic
Slide 5: Agenda
Agenda 01 Introduction For personal use only 02 Cohealyx in acute wound care 03 KOL discussion 04 Closing remarks 05 Q&A Session 5
Slide 6: AVITA is a Hospital-based Acute Wound Care Company
AVITA is a Hospital-based Acute Wound Care Company For personal use only Procedure-driven Repeat product Increasing value acute care utilization by the per case through delivered by same clinicians deeper use specialized across multiple within existing hospital teams patient episodes accounts 6
Slide 7: Our Portfolio Includes Three Distinct Technologies
Our Portfolio Includes Three Distinct Technologies For personal use only RECELL®, RECELL GO and Cohealyx is a collagen PermeaDerm® is a temporary, RECELL GO mini convert a dermal matrix that enables transparent biosynthetic wound small sample of a patient’s skin vascularization and prepares matrix t
Slide 8: Portfolio Designed to Optimize the Healing Pathway
Portfolio Designed to Optimize the Healing Pathway For personal use only Our technologies are PREPARE THE WOUND BED Temporary designed to improve matrix each stage of acute wound healing accelerating recovery, Dermal REBUILD THE FOUNDATION improving efficiency, matrix and reducing burden of care. Ep
Slide 9: Wound Beds Need to Be Optimized to Support Skin Graft
Wound Beds Need to Be Optimized to Support Skin Graft For personal use only Limited vascular supply Optimize Poor Vascularization Vascularized Tissue Support Poor Graft Successful Graft Take and Healing Take and Healing 9
Slide 10: Faster Closure to Improve Patient & System Outcomes
Faster Closure to Improve Patient & System Outcomes For personal use only Stage 2: Skin Graft+RECELL Impacts of Delay Mean time to skin graft • Risk of wound infection • Pain and discomfort 33.2 days1 • Risk of scarring & impairment 95% CI (28.0, 38.4) • Financial burden on patient • Healthcare reso
Slide 11: Consistent Signal: Reduction in Time to Grafting
Consistent Signal: Reduction in Time to Grafting For personal use only 1 2-5 6,7 1. Bush et al. Cureus 2025, 2. Gibson et al. Cureus 2025, 3. Akpunonu et al. J Surg 2025, 4. Castanon et al. Boswick 2026 Conference, 5. Lopez et al. ABA 2026 Conference, 6. ClinicalTrials.gov identifier: NCT06750809, 7
Slide 12: Building Cohealyx Evidence: US Multi-center Trial
Building Cohealyx Evidence: US Multi-center Trial For personal use only Goal: Advance wound bed preparation & readiness for closure Akron Children’s Hospital (Dr. Khandelwal) Chippenham Hospital (Dr. Drake) John Peter Smith Hospital (Dr. Chen) Mass General Brigham (Dr. Goverman) Mercy Hospital Sprin
Slide 13: Building Cohealyx Evidence: US Multi-center Trial
Building Cohealyx Evidence: US Multi-center Trial Primary Endpoint For personal use only Time to skin grafting compared to objective performance goal1 Target Patient Population Stage 2: ➢ Acute full-thickness wound Skin Graft+RECELL ➢ Staged surgical procedure ➢ No TBSA limitation Primary Endpoint ➢
Slide 14: Interim Analysis: Primary Endpoint Established
Interim Analysis: Primary Endpoint Established 33.2 For personal use only Mean Days to Grafting 19.6 Days: Earlier than Control Mean Control dermal matrices 11 Days: Median Time to Skin Graft 13.6 5 Days: Earliest Time to Skin Graft P < 0.001* *One-sample t-test with a 0.025 significance level compa
Slide 15: Early Grafting Achieved in the Majority of Patients
Early Grafting Achieved in the Majority of Patients 72% ≤14 Days For personal use only 25% ≤7 Days 5 Patients Grafted 4 4 3 3 2 2 2 2 2 2 2 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 0// 50 61 15 1. ClinicalTrials.gov identifier:
Slide 16: 90% Investigator Satisfaction Across Patient Cases
90% Investigator Satisfaction Across 40 Patient Cases For personal use only Very Dissatisfied 0.0% Dissatisfied 5.0% Neutral 5.0% Satisfied 32.5% Very Satisfied 57.5% Asked at time of grafting for each patient: “How satisfied are you with the treatment in this study?” (n=40) 16 1. ClinicalTrials.gov
Slide 17: Cohealyx-I Patient
Cohealyx-I Patient 62-year-old male │ 496 cm2 Right Torso│COPD For personal use only Presentation Post-excision ClinicalTrials.gov identifier: NCT06750809. 17
Slide 18: Cohealyx-I Patient
Cohealyx-I Patient Cohealyx Application Post-Cohealyx Application For personal use only ClinicalTrials.gov identifier: NCT06750809. 18
Slide 19: Cohealyx-I Patient
Cohealyx-I Patient Day 11 Post-Cohealyx Application Day 11 Post-Cohealyx Application For personal use only Autograft Ready at Day 11 ClinicalTrials.gov identifier: NCT06750809. 19
Slide 20: Cohealyx-I Patient
Cohealyx-I Patient Day 7 Post-skin graft Day 14 Post-skin graft 8 Weeks Post-skin graft For personal use only 20 ClinicalTrials.gov identifier: NCT06750809.
Slide 21: Key Takeaways
Key Takeaways Stage 2: For personal use only Skin Graft+RECELL Stage 1: Cohealyx ➢ Time to grafting for Cohealyx is significantly reduced compared to control dermal matrices with grafting as early as 5 days1 ➢ Primary endpoint reflects how efficiently patients reach closure, central to clinical outc
Slide 22: First Patient Experience at Our Institution
First Patient Experience at Our Institution 55-year-old male │ 170.5 cm2 left upper leg NSTI │ Heart failure, cirrhosis, obesity hypoventilation syndrome For personal use only Presentation Post-excision Cohealyx Application ClinicalTrials.gov identifier: NCT06750809. NSTI: Necrotizing soft tissue in
Slide 23: First Patient Experience at Our Institution
First Patient Experience at Our Institution 55-year-old male │ 170.5 cm2 left upper leg NSTI │ Heart failure, cirrhosis, obesity hypoventilation syndrome For personal use only Post-Cohealyx Day 6 Post-Cohealyx Day 13 Skin Graft Application Autograft Ready at Day 13 ClinicalTrials.gov identifier: NCT
Slide 24: First Patient Experience at Our Institution
First Patient Experience at Our Institution 55-year-old male │ 170.5 cm2 left upper leg NSTI │ Heart failure, cirrhosis, obesity hypoventilation syndrome For personal use only Post-Cohealyx Day 6 Post-Cohealyx Day 13 Skin Graft Application Scientific Findings Correlate with Pre-clinical Data Dark bl
Slide 25: Key Takeaways
Key Takeaways For personal use only Initial Presentation Cohealyx Day 13 Post-graft Week 12 Performance in Efficient progression Favorable skin real-world clinical patients to skin grafting restoration ClinicalTrials.gov identifier: NCT06750809. 25
Slide 26: Data Communication Strategy
Data Communication Strategy For personal use only Early Full Data Set Full Data Publication Readout Available Readout Q1-Q4 2026 October 2026 Q1-Q4 2027 December 2026 Congresses Congresses Target Submission Single-center Results Multi-center Results Multi-center Results & Histological Data Safety, E
Slide 27: Final Takeaways
Final Takeaways For personal use only Redefining wound Interim data Strong surgeon Drives greater value bed preparation support clinical satisfaction per patient and with faster, more performance and supports adoption reinforces our predictable commercial and expansion procedure-based progression to
Slide 28: Q&A
Q&A For personal use only Cary Vance Katie Bush, PhD Derek Bell, MD Lourdes Castañón, MD, FACS Interim Chief Senior Vice President, University of University of Arizona, Executive Officer Scientific and Medical Rochester Burn & Acute Care Surgery AVITA Medical Affairs Trauma Center, Plastic and Burn